Core Viewpoint - The Hong Kong pharmaceutical sector experienced significant declines, with major companies facing substantial stock price drops on September 11. Company Performance - Tigermed (03347.HK) saw a decline of 14.06% - Viva Biotech (01873.HK) dropped by 11.85% - Kanglong Chemical (03759.HK) fell by 10% - Zai Lab (06172.HK) decreased by 8.26% [1]

Market Overview - The A-share market opened with mixed results, with the Shanghai Composite Index down by 0.16%, the Shenzhen Component Index up by 0.11%, and the ChiNext Index up by 0.46% [3][4] - The Hang Seng Index opened down by 0.81%, and the Hang Seng Tech Index fell by 0.97% [6][7] Pharmaceutical Sector Performance - The innovative drug concept stocks experienced significant declines, with BeiGene falling over 10%, WuXi AppTec and Tigermed down over 7%, and several other companies like Hengrui Medicine, Junshi Biosciences, and Kelun Pharmaceutical dropping over 5% [2][6] - The pharmaceutical sector as a whole saw a downturn, with various sub-sectors such as medical services, weight loss drugs, and CRO concepts all reporting negative performance, with declines ranging from -1.13% to -1.99% [5] Notable Stock Movements - Specific stocks such as Hansoh Pharmaceutical and WuXi Biologics dropped over 10%, while Jiangsu Hengrui Medicine and Junshi Biosciences also faced significant losses [6] - Conversely, some stocks like Jiujiuwang Pharmaceutical saw a rise of 5% despite the overall market trend [6]

Market Overview - The innovative drug concept stocks opened significantly lower, with BeiGene dropping over 10%, WuXi AppTec and Tigermed down over 7%, and several other companies like HengRui Medicine, Junshi Biosciences, and Kelun Pharmaceutical falling over 5% [3][4]. - The A-share market showed mixed results, with the Shanghai Composite Index down 0.16%, while the Shenzhen Component Index rose 0.11% and the ChiNext Index increased by 0.46% [4][5]. Sector Performance - The healthcare sector experienced a decline, with various sub-sectors such as medical services, CRO concepts, and innovative drugs all showing negative performance, with declines ranging from -1.99% to -1.44% [6]. - The Hong Kong market also opened lower, with the Hang Seng Index down 0.81% and the Hang Seng Tech Index falling 0.97%. Pharmaceutical stocks in Hong Kong saw significant drops, with companies like Hansoh Pharmaceutical and WuXi Biologics declining over 10% [6][7]. Notable Stocks - Specific stocks highlighted include BeiGene, WuXi AppTec, and Tigermed, which are part of the innovative drug sector and faced substantial declines in their stock prices [3][4]. - In the Hong Kong market, Hansoh Pharmaceutical and WuXi Biologics were noted for their significant drops, while a few stocks like Jiujiuwang Technology showed resilience with a 5% increase [6][7].

Market Overview - The pharmaceutical sector experienced significant declines, with WuXi AppTec and Tigermed opening down over 7% [1][2] - Innovative drug concept stocks also saw substantial drops, with BeiGene falling over 10% and several other companies, including WuXi AppTec and Tigermed, dropping more than 7% [1][2] Index Performance - The Shanghai Composite Index decreased by 0.16%, while the Shenzhen Component Index increased by 0.11%, and the ChiNext Index rose by 0.46% [2][3] - The healthcare services sector fell by 1.99%, with various sub-sectors such as weight loss drugs and CRO concepts also declining [3] Hong Kong Market - The Hang Seng Index opened down 0.81%, and the Hang Seng Tech Index fell by 0.97% [4][5] - Pharmaceutical stocks in Hong Kong saw widespread declines, with Hansoh Pharmaceutical and WuXi Biologics dropping over 10% [4] Currency and Monetary Policy - The People's Bank of China conducted a 7-day reverse repurchase operation of 292 billion yuan at a steady rate of 1.40% [5] - The RMB to USD central parity rate was reported at 7.1034, an increase of 28 basis points from the previous trading day [6]

Company Overview - Tiger Med is located in Hangzhou, Zhejiang Province, and was established on December 15, 2004, with its IPO on August 17, 2012 [1] - The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products, covering I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has cumulatively distributed 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Stock Performance - As of September 9, Tiger Med's stock price was 65.83 yuan per share, with a market capitalization of 56.681 billion yuan [1] - Year-to-date, the stock price has increased by 21.18%, but it has seen a decline of 0.63% over the last five trading days and 1.78% over the last twenty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders was 51,500, a decrease of 4.14% from the previous period [2] - The top ten circulating shareholders include notable funds, with changes in their holdings indicating varying levels of investment interest [3]

Group 1 - The company, Tigermed, announced that it will hold its first extraordinary general meeting of shareholders for 2025 on September 29, 2025 [2] - The meeting will review multiple proposals, including the proposal for amendments [2]

证券代码：300347 证券简称：泰格医药 公告编码（2025）037 号 杭州泰格医药科技股份有限公司 关于召开 2025 年第一次临时股东会的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 一、召开会议的基本情况 1．股东会届次：2025年第一次临时股东会。 2．股东会的召集人：公司董事会。 3．会议召开的合法、合规性：经公司第五届董事会第十八次会议审议通过，决定召 开2025年第一次临时股东会，召集程序符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 4．会议召开的日期、时间： 现场会议召开日期和时间：2025 年9 月29 日（星期一）下午15:00 网络投票日期和时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 9 月 29 日上午 9:15—9:25，9:30—11:30 和下午13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年9 月29 日上午 9:15 至2025 年9 月29 日下午15:00。 5．会议的召开方式：本次股东会采用现场表决与网 ...

杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 2025年9月29日（星期一）舉行的2025年第一次臨時股東大會代表委任表格 本人╱ 吾等 1 地址為 為杭州泰格醫藥科技股份有限公司（「本公司」）股本中每股面值人民幣1.00元股份 股 2 H股登記持有人，茲委任大會主席 3 或 地址為 HANGZHOU TIGERMED CONSULTING CO., LTD. 日期：2025年 月 日 簽署 5 ： 附註： 收集個人資料聲明 本代表委任表格所指的「個人資料」具有《個人資料（私隱）條例》（第486章）（「私隱條例」）賦予「個人資料」之相同 涵義，當中包括 閣下及 閣下代表的姓名及地址。 為本人╱ 吾等的受委代表，代表本人╱ 吾等出席本公司謹訂於2025年9月29日（星期一）下午 三時正假座中國杭州市濱江區聚工路19號盛大科技園A座18樓會議室舉行2025年第一次臨 時股東大會（「臨時股東大會」）及其任何續會，以考慮及酌情通過載於臨時股東大會通告的 決議案，並於臨時股東大會及其任何續會代表本人╱ 吾等並以本人╱ 吾等名義就下述決議 案按以下方式投票。除非另有說明 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 2025年第一次臨時股東大會通告 茲通告 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）謹 定 於2025年9月29日 （星 期 一）下 午 三 時 正 假 座 中 國 杭 州 市 濱 江 區 聚 工 路19號盛大科技園A座 18樓會議室舉行2025 年 第 一 次 臨 時 股 東 大 會（「臨時股東大會」）或 其 任 何 續 會，藉 以 考 慮 並 酌 情 批 准 下 列 決 議 案。除 文 義 另 有 所 指 外，本 通 告 所 用詞彙與本公司日期為2025年9月9日（星 期 二）之 通 函（「通 ...

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚賴該等內容而 引致之任何損失承擔任何責任。 閣下如對本通函任何內容或應採取之行動有任何疑問，應諮詢持牌證券交易商、銀行經理、律師、專業 會計師或其他專業顧問。 閣下如已將名下之杭州泰格醫藥科技股份有限公司股份全部出售或轉讓，應立即將本通函連同代表委 任表格送交買主或承讓人，或經手買賣或轉讓之銀行、或持牌證券交易商或其他代理商，以便轉交買主 或承讓人。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） (1) 建議修訂《公司章程》； (4) 建議減少註冊資本； (10) 建議修訂《信息披露管理制度》； (11) 建議授權公司管理層與公司審計機構協商年度審計費用； 以及 釋 義 於本通函內，除文義另有所指外，下列詞彙具備以下涵義： (12) 2025年第一次臨時股東大會通告 本通函全部用語之涵義載於本通函「 ...